Víctor Burgueño Sandoval
Ayudante de investigación
Research group
Chemistry degree (2018) Universidad de Barcelona. Master in Molecular Biotechnology (2019) Universidad de Barcelona.
Professional network profiles
Last Publications
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
- Cuadrado-Vilanova M, Burgeño-Sandoval V, Balaguer-Lluna L, Aschero MR, Castillo H, Liu, J, Pérez-Jaume S, Pascual-Pastó G, Gene-Olaciregui N, Gomez-Gonzalez S, Correa, G, Suñol M, Schaiquevich, P, Radvanyi, F, Lavarino C, Mora J, Català-Mora J, Chantada G and Carcaboso AM Follow-up of intraocular retinoblastoma through the quantitative analysis of conserved nuclear DNA sequences in aqueous humor from patients JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 9(1): 32-43.
- Cuadrado-Vilanova M, Liu J, Paco-Mercader S, Aschero MR, Burgeño-Sandoval V, Sirab N, Pascual-Pastó G, Correa G, Balaguer-Lluna L, Castillo H, Pérez-Jaume S, Muñoz-Aznar O, Roldan-Molina M, Suñol M, Schaiquevich P, Aerts I, Doz F, Cassoux N, Lubieniecki F, Benitez-Ribas D, Lavarino C, Mora J, Chantada G, Català-Mora J, Radvanyi F and Carcaboso AM Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. JOURNAL OF PATHOLOGY . 257(3): 327-339.
Projects
- Project name:
- Immune microenvironment of retinoblastoma
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00216
- Starting - finishing date:
- 2022 - 2024
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2024
- Project name:
- Inhibition of the PI3K/Akt pathway in pediatric high grade and diffuse intrinsic pontine gliomas (pHGG/DIPG)
- Leader
- Angel Montero Carcaboso
- Funding entities:
- ZZZZ_O.H.S.J.D.-Curia Provincial
- Code
- BECA BOMBERS 2019
- Starting - finishing date:
- 2020 - 2023
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
A nanomedicine to improve treatment of Ewing sarcoma
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.